Immunterápia a vesedaganatok kezelésében
The authors briefly highlight the results of targeted therapy and present new solutions in kidney cancer immunotherapy. The important checkpoint inhibitors (anti-CTLA-4, -PD-1 and -PD-L1/2) and their combinations, together with the combinations of targeted drugs and immunotherapy are discussed. The...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2017
|
| Sorozat: | MAGYAR ONKOLÓGIA
61 No. 2 |
| mtmt: | 3274136 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/12048 |
| LEADER | 01225nab a2200217 i 4500 | ||
|---|---|---|---|
| 001 | publ12048 | ||
| 005 | 20200213160449.0 | ||
| 008 | 171007s2017 hu o 0|| zxx d | ||
| 022 | |a 0025-0244 | ||
| 024 | 7 | |a 3274136 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Géczi Lajos | |
| 245 | 1 | 0 | |a Immunterápia a vesedaganatok kezelésében |h [elektronikus dokumentum] / |c Géczi Lajos |
| 260 | |c 2017 | ||
| 300 | |a 126-131 | ||
| 490 | 0 | |a MAGYAR ONKOLÓGIA |v 61 No. 2 | |
| 520 | 3 | |a The authors briefly highlight the results of targeted therapy and present new solutions in kidney cancer immunotherapy. The important checkpoint inhibitors (anti-CTLA-4, -PD-1 and -PD-L1/2) and their combinations, together with the combinations of targeted drugs and immunotherapy are discussed. The newest checkpoint agents, vaccination and pegylated interleukin-2 are also presented. The most promising clinical trials (CheckMate-025, AGS-003, IMA 901) and the on-going first line phase III trials are shown in metastatic clear cell renal carcinoma. | |
| 700 | 0 | 1 | |a Nagyiványi Krisztián András |e aut |
| 700 | 0 | 1 | |a Maráz Anikó |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/12048/1/0126a.pdf |z Dokumentum-elérés |